AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17504903 — intervention group
Group type: COMPARATOR
Intervention: Heat treatment
Number of subjects: 72
Study 17504903 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) plus LNG
Number of subjects: 72
Study 17504903 — intervention group
Group type: COMPARATOR
Intervention: Heat treatment only
Number of subjects: 72
Study 16243723 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Number of subjects: 178
Study 16243723 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity physical activity
Number of subjects: 178
Study 12495242 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control feedback
Number of subjects: 0
Study 12495242 — intervention group
Group type: COMPARATOR
Intervention: Yoked feedback
Number of subjects: 0
Study 9653685 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization and comprehensive treatment (hot packs, active range of motion, physiologic stretching, muscle strengthening, soft tissue mobilization, and patient education)
Number of subjects: 14
Study 9653685 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization and comprehensive treatment
Number of subjects: 14
Study 9653685 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive treatment alone
Number of subjects: 14
Study 7505819 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP (18.5 MBq or 37 MBq per kg body weight)
Number of subjects: 19
Study 7505819 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP
Number of subjects: 19
Study 2686575 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 194
Study 2686575 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 194
Study 2686575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 30269562 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR40 and BFR50
Number of subjects: 12
Study 30269562 — intervention group
Group type: COMPARATOR
Intervention: HI-RE
Number of subjects: 12
Study 30269562 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR70 and BFR80
Number of subjects: 12
Study 30269562 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR60, BFR70, and BFR80
Number of subjects: 12
Study 26522708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks through week 24 and every 8 weeks through week 48.
Number of subjects: 0
Study 26522708 — intervention group
Group type: COMPARATOR
Intervention: Grid laser at baseline and IAI every 8 weeks after 3 monthly doses from week 24 onward (laser/IAI group).
Number of subjects: 0
Study 26522708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg.
Number of subjects: 0
Study 26522708 — intervention group
Group type: COMPARATOR
Intervention: Grid laser and IAI (laser/IAI group).
Number of subjects: 0
Study 25632802 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES) before SEMS placement
Number of subjects: 200
Study 25632802 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic sphincterotomy (non-ES) before SEMS placement
Number of subjects: 200
Study 24029269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 500 mg twice/day
Number of subjects: 50
Study 24029269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal fascia
Number of subjects: 117
Study 21921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tragus perichondrium
Number of subjects: 117
Study 21921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tragus cartilage‐perichondrium composite grafts
Number of subjects: 117
Study 21921853 — intervention group
Group type: COMPARATOR
Intervention: Small perforation group (all interventions)
Number of subjects: 117
Study 21921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporalis fascia or perichondrium (for large perforations)
Number of subjects: 117
Study 18556747 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin-containing PD solutions (Extraneal)
Number of subjects: 722
Study 18556747 — intervention group
Group type: COMPARATOR
Intervention: Non-icodextrin-containing PD solutions
Number of subjects: 722
Study 18556747 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin from two independent manufacturers
Number of subjects: 722
Study 18556747 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-icodextrin)
Number of subjects: 722
Study 16979005 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Number of subjects: 187
Study 16979005 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic Therapy (PT) alone
Number of subjects: 187
Study 14551366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spironolactone (25 mg three times/week)
Number of subjects: 35
Study 11256554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (450 mg/day)
Number of subjects: 30
Study 11256554 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 microg/day)
Number of subjects: 30
Study 11256554 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators alone
Number of subjects: 30
Study 9164896 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 9164896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8171288 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated peroral charcoal (50 g 3 times a day for 8 days)
Number of subjects: 19
Study 8171288 — intervention group
Group type: COMPARATOR
Intervention: Normal follow-up (Control)
Number of subjects: 19
Study 3146125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g single dose at the time of surgery)
Number of subjects: 113
Study 3146125 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 113
Study 30831453 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie deprivation for two days
Number of subjects: 23
Study 28159854 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Reporting and Action for a Safe Environment (PRASE) intervention
Number of subjects: 86
Study 28159854 — intervention group
Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 86
Study 25335876 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P seminar series
Number of subjects: 143
Study 25335876 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 143
Study 22752286 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP = 10 cmH(2)O (PEEP group, n = 30)
Number of subjects: 60
Study 22752286 — intervention group
Group type: COMPARATOR
Intervention: No external PEEP (ZEEP group, n = 30)
Number of subjects: 60
Study 22752286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PEEP and ZEEP)
Number of subjects: 60
Study 21764711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 60
Study 21764711 — intervention group
Group type: COMPARATOR
Intervention: 3-D conformal radiotherapy (3-DCRT)
Number of subjects: 60
Study 21764711 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 60
Study 21764711 — intervention group
Group type: COMPARATOR
Intervention: 3-DCRT
Number of subjects: 60
Study 18585635 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy with maintenance protocol
Number of subjects: 0
Study 18585635 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 0
Study 18585635 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy with maintenance treatment
Number of subjects: 0
Study 18585635 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG maintenance treatment
Number of subjects: 0
Study 18585635 — intervention group
Group type: EXPERIMENTAL
Intervention: SWOG protocol for BCG therapy
Number of subjects: 0
Study 18585635 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose of BCG
Number of subjects: 0
Study 18585635 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized approach to BCG therapy
Number of subjects: 0
Study 17238456 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12623474 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol orally
Number of subjects: 496
Study 12623474 — intervention group
Group type: COMPARATOR
Intervention: 10 IU oxytocin intramuscularly
Number of subjects: 496
Study 10999784 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (500 mg every 4 h)
Number of subjects: 12
Study 10999784 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 9081136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 60 micrograms, intravenous infusion, 5 days a week for 4 weeks, followed by twice a week for 4 weeks
Number of subjects: 213
Study 9081136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 213
Study 9081136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 31969545 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond™FL
Number of subjects: 159
Study 31969545 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond®NT™
Number of subjects: 159
Study 31969545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil™SE Bond
Number of subjects: 159
Study 31969545 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno®III
Number of subjects: 159
Study 31969545 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno®V+
Number of subjects: 159
Study 31969545 — intervention group
Group type: COMPARATOR
Intervention: Etch‐and‐rinse adhesives (combined performance)
Number of subjects: 159
Study 30127194 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (100%)
Number of subjects: 60
Study 30127194 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyol chewing gum
Number of subjects: 60
Study 30127194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 60
Study 29231562 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife combined with pseudo-ginseng-cake moxibustion
Number of subjects: 60
Study 29231562 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of western medication
Number of subjects: 60
Study 24405492 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold suspend (TS) feature, insulin stopped for 2 hours once SG value of ≤70 mg/dL detected
Number of subjects: 50
Study 24405492 — intervention group
Group type: COMPARATOR
Intervention: Control (basal insulin delivery continued)
Number of subjects: 50
Study 24405492 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold suspend (TS) feature
Number of subjects: 50
Study 22168429 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideCoach and verbal feedback
Number of subjects: 19
Study 22168429 — intervention group
Group type: COMPARATOR
Intervention: Video and verbal feedback
Number of subjects: 19
Study 22168429 — intervention group
Group type: COMPARATOR
Intervention: Video feedback
Number of subjects: 19
Study 19931156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg as an intermittent bolus 3 times a day)
Number of subjects: 20
Study 19931156 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (40 mg as an intermittent bolus twice a day)
Number of subjects: 20
Study 16671978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for migraine
Number of subjects: 0
Study 16671978 — intervention group
Group type: COMPARATOR
Intervention: Control interventions (not specified)
Number of subjects: 0
Study 15288222 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the vaginal vault
Number of subjects: 135
Study 15288222 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the cervix
Number of subjects: 135
Study 15288222 — intervention group
Group type: COMPARATOR
Intervention: No PCB
Number of subjects: 135
Study 11703890 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's safer sex hierarchy of prevention methods (hierarchy cohort)
Number of subjects: 292
Study 11703890 — intervention group
Group type: COMPARATOR
Intervention: Male condom only (MC cohort)
Number of subjects: 292
Study 11703890 — intervention group
Group type: COMPARATOR
Intervention: Female condom only (FC cohort)
Number of subjects: 292
Study 9135288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Number of subjects: 91
Study 9135288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 8689733 — intervention group
Group type: EXPERIMENTAL
Intervention: Geristore restoration system after cavity cleaned with 10% NaOCl solution and 3% H2O2 solution (Group G)
Number of subjects: 22
Study 8689733 — intervention group
Group type: COMPARATOR
Intervention: Geristore restoration system after cavity applied with Mirage-Bond (Group MG)
Number of subjects: 22
Study 3583500 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole 900 mg
Number of subjects: 19
Study 3583500 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole 1800 mg
Number of subjects: 19
Study 3583500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31038442 — intervention group
Group type: EXPERIMENTAL
Intervention: Figurative art
Number of subjects: 77
Study 31038442 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern art
Number of subjects: 77
Study 31038442 — intervention group
Group type: COMPARATOR
Intervention: Museum office (control)
Number of subjects: 77
Study 28266950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine (group RD)
Number of subjects: 45
Study 28266950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Tramadol (group RT)
Number of subjects: 45
Study 28266950 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (group R)
Number of subjects: 45
Study 28266950 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 26614615 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centred critical care discharge information pack (UCCDIP)
Number of subjects: 158
Study 26614615 — intervention group
Group type: COMPARATOR
Intervention: Ad hoc verbal information (control 1)
Number of subjects: 158
Study 26614615 — intervention group
Group type: COMPARATOR
Intervention: Booklet published by ICUsteps (control 2)
Number of subjects: 158
Study 23971455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion management application
Number of subjects: 50
Study 23971455 — intervention group
Group type: COMPARATOR
Intervention: Manual method
Number of subjects: 50
Study 21926186 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100mg + placebo
Number of subjects: 1081
Study 21926186 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50mg + methotrexate
Number of subjects: 1081
Study 21926186 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100mg + methotrexate
Number of subjects: 1081
Study 21926186 — intervention group
Group type: COMPARATOR
Intervention: subcutaneous placebo + methotrexate
Number of subjects: 1081
Study 21926186 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP changes at week 4
Number of subjects: 1081
Study 21926186 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMRIS scores at week 12
Number of subjects: 1081
Study 21926186 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and clinical/laboratory/radiographic measures
Number of subjects: 1081
Study 21926186 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in MRI and clinical/radiographic measures
Number of subjects: 1081
Study 18434462 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 25
Study 18434462 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study 16763968 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-voxel point resolved spectroscopy at 4.0 T in anterior cingulate
Number of subjects: 53
Study 16763968 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-voxel point resolved spectroscopy at 4.0 T in hippocampus
Number of subjects: 53
Study 16763968 — intervention group
Group type: COMPARATOR
Intervention: Variability measurements in healthy subjects
Number of subjects: 53
Study 16763968 — intervention group
Group type: COMPARATOR
Intervention: Calculations for detecting differences in NAA
Number of subjects: 53
Study 15343195 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 42
Study 15343195 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin injection therapy
Number of subjects: 42
Study 15343195 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 42
Study 11177203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-rich mineral water (1715 mg bicarbonate/l)
Number of subjects: 0
Study 11177203 — intervention group
Group type: COMPARATOR
Intervention: Sodium potassium citrate
Number of subjects: 0
Study 9051880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 0.5 g daily for 2 years
Number of subjects: 116
Study 9051880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 8378156 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (50 mg/kg)/promethazine (1 mg/kg)
Number of subjects: 24
Study 8378156 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg)/promethazine (1 mg/kg)
Number of subjects: 24
Study 2878859 — intervention group
Group type: EXPERIMENTAL
Intervention: Azodisal sodium (1 g/day)
Number of subjects: 18
Study 2878859 — intervention group
Group type: COMPARATOR
Intervention: Azodisal sodium (1 g/day vs 2 g/day)
Number of subjects: 18
Study 2878859 — intervention group
Group type: EXPERIMENTAL
Intervention: Azodisal sodium (2 g/day)
Number of subjects: 18
Study 2878859 — intervention group
Group type: COMPARATOR
Intervention: Placebo or sulphasalazine (2 g/day)
Number of subjects: 18
Study 30292613 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access of the common femoral artery (CFA) with a percutaneous closure device
Number of subjects: 274
Study 30292613 — intervention group
Group type: COMPARATOR
Intervention: Open surgical access of the CFA
Number of subjects: 274
Study 30292613 — intervention group
Group type: EXPERIMENTAL
Intervention: MDs only (for percutaneous access)
Number of subjects: 274
Study 30292613 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access
Number of subjects: 274
Study 30292613 — intervention group
Group type: COMPARATOR
Intervention: Open surgical access
Number of subjects: 274
Study 30292613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal or groin Staphylococcus aureus carriage
Number of subjects: 274
Study 29348326 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed histone inheritance
Number of subjects: 0
Study 29348326 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized inheritance of preexisting histones versus newly synthesized histones
Number of subjects: 0
Study 24215715 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator® attachments
Number of subjects: 46
Study 24215715 — intervention group
Group type: COMPARATOR
Intervention: Dolder® bar
Number of subjects: 46
Study 24377219 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming-promoting needling and target penetrating needling method (WT group)
Number of subjects: 90
Study 24377219 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (CA group)
Number of subjects: 90
Study 24377219 — intervention group
Group type: COMPARATOR
Intervention: Medication (M group)
Number of subjects: 90
Study 21490928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing a stranger's voice as feedback
Number of subjects: 0
Study 21490928 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (hearing their own voice as feedback)
Number of subjects: 0
Study 21490928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing a stranger's voice (illusion present)
Number of subjects: 0
Study 21490928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing a stranger's voice (illusion broken)
Number of subjects: 0
Study 19922881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 microg
Number of subjects: 120
Study 19922881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 microg
Number of subjects: 120
Study 19922881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 120
Study 19922881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% isotonic saline)
Number of subjects: 120
Study 17074269 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCare (SC group, n = 13)
Number of subjects: 38
Study 17074269 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing Trials (SBT group, n = 25)
Number of subjects: 38
Study 14746859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg, ondansetron 32 mg i.v., dexamethasone 12 mg on day 1, aprepitant 80 mg and dexamethasone 8 mg on days 2-3, dexamethasone 8 mg on day 4
Number of subjects: 1038
Study 14746859 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ondansetron 32 mg i.v. and dexamethasone 20 mg on day 1, dexamethasone 8 mg b.i.d. on days 2-4)
Number of subjects: 1038
Study 11762560 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 microg
Number of subjects: 14
Study 11762560 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1000 microg
Number of subjects: 14
Study 11762560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 microg
Number of subjects: 14
Study 11762560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg
Number of subjects: 14
Study 11762560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9373703 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 15
Study 9373703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8510490 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month course of alfa interferon therapy
Number of subjects: 61
Study 8510490 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated cases)
Number of subjects: 61